Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One Patent, Six Patent Applications Related to RNAi: Oct 16, 2008

Premium
Title: Process for Delivery of Polynucleotides to the Prostate
 
Number: 7,435,723
 
Filed: Oct. 6, 2003
 
Lead Inventor: James Hagstrom, Mirus Bio (Roche)
 
The patent, its abstract states, claims “a system for providing in vivo delivery of polynucleotides to mammalian prostate cells using an intravascular administration route. The polynucleotides are inserted in an injection solution into a mammalian vasculature. Insertion of the injection solution at an appropriate rate increases the volume of extravascular fluid in the tissue thereby facilitating delivery of the polynucleotide to the cell.”
 

 
Title: Genetic Inhibition of Double-Stranded RNA
 
Number: 20080248576
 
Filed: Sept. 28, 2007
 
Lead Inventor: Andrew Fire, Carnegie Institution
 
The patent application, its abstract states, claims a process of “introducing an RNA into a living cell to inhibit gene expression of a target gene in that cell. The process may be practiced ex vivo or in vivo. The RNA has a region with double-stranded structure. Inhibition is sequence-specific in that the nucleotide sequences of the duplex region of the RNA and of a portion of the target gene are identical.”
 
The invention, the abstract adds, “is distinguished from prior art interference in gene expression by antisense or triple-strand methods.”
 

 
Title: Modified Short Interfering RNA
 
Number: 20080249039
 
Filed: Jan. 28, 2005 PCT Filed: Jan. 28, 2005
 
Lead Inventor: Joacim Elmen, Santaris Pharma
 
According to the patent application’s abstract, the invention “is directed to modified siRNA which are significantly impaired in their ability to support cleavage of mRNA when incorporated into a RISC complex. Such modified siRNA may be useful as therapeutic agents, e.g., in the treatment of various cancer forms. More particularly, the modified siRNA comprises a sense strand and an antisense strand, wherein the sense strand contains a modified RNA nucleotide in at least one of positions 8 [to] 14, calculated from the 5' end.”
 

 
Title: RNA Interference-Mediated Inhibition of Sterol Regulatory Element Binding Protein 1 Gene Expression Using Short Interfering Nucleic Acid
 
Number: 20080249040
 
Filed: July 19, 2006
 
Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)
 
The invention, the patent application’s abstract states, “relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases, and conditions that respond to the modulation of sterol regulatory element-binding protein 1 gene expression and/or activity. The … invention is also directed to compounds, compositions, and methods relating to traits, diseases, and conditions that respond to the modulation of expression and/or activity of genes involved in SREBP1 gene expression pathways or other cellular processes that mediate the maintenance or development of such traits, diseases, and conditions.
 
“Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid molecules … capable of mediating RNA interference against SREBP1 gene expression, including cocktails of such small nucleic acid molecules and lipid nanoparticle formulations of such small nucleic acid molecules,” the abstract notes. The invention also “relates to small nucleic acid molecules, such as siNA, siRNA, and others that can inhibit the function of endogenous RNA molecules … or endogenous short interfering RNA … that can inhibit the function of RISC to modulate SREBP1 gene expression by interfering with the regulatory function of such endogenous RNAs or proteins associated with such endogenous RNAs. … Such small nucleic acid molecules and are useful, for example, in providing compositions to prevent, inhibit, or reduce metabolic diseases traits and conditions, including but not limited to hyperlipidemia, hypercholesterolemia, cardiovascular disease, atherosclerosis, hypertension, diabetes, insulin resistance, obesity, and/or other disease states, conditions, or traits associated with SREBP1 gene expression or activity in a subject or organism.”
 

 
Title: Modified siRNA Molecules and Uses Thereof
 
Number: 20080249046
 
Filed: June 8, 2007
 
Lead Inventor: Ian MacLachlan, Protiva Biotherapeutics (Tekmira Pharmaceuticals)
 
The invention, the patent application’s abstract states, “provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains full RNAi activity against the target sequence. The … invention also provides nucleic acid-lipid particles comprising a modified siRNA, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods for identifying and/or modifying an siRNA having immunostimulatory properties are also provided.”
 

 
Title: Methods and Compositions for the Treatment of Intestinal Conditions
 
Number: 20080249048
 
Filed: Sept. 20, 2007
 
Lead Inventor: Ana Jimenez, Sylentis
 
The patent application, its abstract states, claims “methods and compositions for the treatment of intestinal disorders, such as IBD and Crohn's disease. …Preferred compositions include siNA. Also disclosed is a method of specifically targeting siNA to treat intestinal disorders by intrarectal administration of siNA compounds.”
 

 
Title: Method for Improved Selection of RNAi Transfectants
 
Number: 20080248468
 
Filed: Dec. 13, 2005, PCT Filed: Dec. 13, 2005
 
Lead Inventor: Manfred Kubbies, Hoffman-La Roche
 
The invention, according to the patent application’s abstract, “is directed to a method for inactivation of expression of a gene in a eukaryotic cell comprising [the] transfection of a eukaryotic cell with DNA comprising an expression cassette for expression of a cell surface protein and an expression cassette for expression of a RNAi compound … capable of inactivating expression of said gene, wherein said expression cassette for expression of a cell surface protein and said expression cassette for expression of a RNAi compound are located on the same vector DNA.”
 
The method further includes the “enrichment and/or selection of cells which express said cell surface protein,” the abstract adds.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.